Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03700294 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
A Phase 1 study, sponsored by ADC Therapeutics S.A..
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03700294 is a Phase 1 study that was terminated before completion, run by ADC Therapeutics S.A.. The registered enrollment target is 18 participants.
The verdict
NCT03700294, a Phase 1 study, was terminated before completion, sponsored by ADC Therapeutics S.A..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study evaluates the safety, tolerance, pharmacokinetics (PK), and antitumor activity of ADCT-601 in patients with advanced solid tumors.
Interventions
- DRUG ADCT-601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03700294
The ClinicalTrials.gov registry entry for NCT03700294 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADCT-601 is the first listed.
NCT03700294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03700294 about?
NCT03700294 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors". This study evaluates the safety, tolerance, pharmacokinetics (PK), and antitumor activity of ADCT-601 in patients with advanced solid tumors.
What is the current status of trial NCT03700294?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-12-21. Estimated completion is 2019-12-11.
What interventions are being tested in trial NCT03700294?
The interventions under investigation include: ADCT-601 (DRUG).
Who is sponsoring clinical trial NCT03700294?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.